Donor alloantigen-specific alloreactive effector T cells (AST)

Donor alloantigen-specific alloreactive effector T cells are a specialized population of T lymphocytes that play a central role in the immune response following transplantation. These cells are characterized by their ability to recognize non-self Major Histocompatibility Complex (MHC) molecules, or alloantigens, presented on the surface of donor or recipient cells (Janeway's Immunobiology, 9th Ed). In the context of hematopoietic stem cell transplantation, donor-derived T cells recognize the recipient's tissues as foreign, leading to Graft-versus-Host Disease (GvHD) (StatPearls, Graft Versus Host Disease, 2023). In solid organ transplantation, recipient T cells recognize the donor graft, leading to acute or chronic rejection. The activation of these cells involves complex signaling pathways, including the T-cell receptor (TCR) engagement and costimulatory signals such as CD28-CD80/86. Therapeutic targeting of these cells is essential for transplant success and involves various strategies to modulate the immune response. Common pharmacological interventions include calcineurin inhibitors like tacrolimus, which prevent T-cell activation by blocking IL-2 production (PubChem, Tacrolimus), and mTOR inhibitors like sirolimus, which inhibit T-cell proliferation. Biologic agents such as abatacept target costimulatory pathways to induce anergy (FDA Label, Orencia), while depleting antibodies like antithymocyte globulin (ATG) directly reduce the number of circulating alloreactive T cells. Monitoring these cells through biomarkers like CD25 expression or interferon-gamma production is crucial for assessing the risk of rejection or GvHD. However, broad suppression of these cells carries significant safety concerns, including an increased susceptibility to opportunistic infections and the development of secondary malignancies.

Other names

Alloreactive T cellsDonor-specific T cellsGraft-versus-host T cellsAllo-primed T cellsAlloreactive T lymphocytes

Inhibition of T-cell activation, proliferation, and effector function through calcineurin inhibition, mTOR inhibition, costimulation blockade, and direct cellular depletion.